Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virol…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data ...

Johnson & Johnson: TECVAYLI plus DARZALEX FASPRO combination regimen significantly improves progression-free survival and overall survival versus standard of care

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line ...
FXEmpire.com

Natural Gas News: Bulls Target $3.300 as Supply Tightens and Chart Levels Hold

NASDAQ Index, SP500, Dow Jones Forecasts – Stocks Gain Ground As Traders Bet On Dovish Fed After Powell’s SpeechTue, 14 Oct 2025 19:27:18 GMT Natural Gas, WTI Oil, Brent Oil Forecasts – Oil Tests New ...